Core Insights - Instil Bio, Inc. has received FDA clearance for the Investigational New Drug (IND) application for AXN-2510, a bispecific antibody targeting PD-L1 and VEGF, aimed at treating multiple solid tumors [1][3] - The company plans to initiate a phase 1 trial of AXN-2510 as a monotherapy for patients with relapsed/refractory solid tumors before the end of 2025 [2] - Initial safety and efficacy results from a phase 2 trial of AXN-2510 in combination with chemotherapy for first-line non-small cell lung cancer (NSCLC) in China are expected to be shared in the second half of 2025 [1][2] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies [3] - The lead asset, AXN-2510, is positioned as a differentiated treatment option for various solid tumors [3]

Core Insights - Instil Bio, Inc. has appointed John Maraganore, Ph.D., to the Board of Directors of its subsidiary Axion Bio, Inc., which is focused on developing AXN-2510, a PD-L1xVEGF bispecific antibody targeting solid tumors, particularly non-small cell lung cancer (NSCLC) [1][2] - The appointment is aimed at enhancing leadership to maximize the value of the AXN-2510 program for both patients and shareholders, with expectations of redefining the standard of care for solid tumors [2] - AXN-2510 is currently in a Phase 2 trial in combination with chemotherapy for first-line NSCLC, with early signs of safety and efficacy being reported [2] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company dedicated to developing novel therapies, with AXN-2510 as its lead asset [3] - Axion Bio, a wholly-owned subsidiary of Instil Bio, is specifically focused on the development of AXN-2510 for multiple solid tumors [4] Leadership Background - Dr. John Maraganore brings over 30 years of biotechnology experience, having previously served as the founding CEO of Alnylam Pharmaceuticals, where he led the company to a market capitalization exceeding $40 billion [2] - His expertise spans drug discovery, clinical development, and strategic partnerships, making him a valuable asset for guiding the advancement of next-generation cancer therapies [2]